PharmaLink acquires PharmaReturns

PharmaLink, Inc., a leading pharmaceutical reverse distributor, announced its acquisition of Cybornetic Systems, Inc. dba PharmaReturns, Inc. In addition to expanding its national account base with top-tier clients, the purchase provides PharmaLink with an innovative technology platform for returns processing that adds artificial intelligence (AI) and new levels of customization to the reverse distribution process for pharmaceutical manufacturers. The Internet Managed Product Returns Solution (IMPRS) currently supports returns processing operations for over 400 pharmaceutical manufacturers in the United States. PharmaLink CEO & president, Thierry Beckers, was noted saying, "The leadership team at PharmaReturns has a long history of trailblazing innovation in our industry. With shared values of integrity, quality, customer focus, and innovation, this transaction was a natural fit that greatly benefits our business; and more importantly our customers." The transaction will be complete in June while systems integration runs through year-end 2023. The integration process will be carefully managed to ensure a smooth transition for both teams and prevent any disruption to ongoing client operations. Adam Bottie (vice president, corporate strategy & business development) stated, "We are excited to expand our offering and capabilities to the pharmaceutical manufacturing community, the integration of Encore and IMPRS is going to be a key element in our overall commitment to quality and a catalyst to ensure our competitive advantage in the space." As part of the acquisition, Cybornetic Systems, Inc., CyberCore Systems, Inc., PharmaReturns, Inc., and Return Product Solutions, Inc., as well as IMPRS and all other technology assets, will become the property of PharmaLink. PharmaLink, Inc. is the nation's premier Pharmaceutical Reverse Distribution provider. With services spanning the complete spectrum of the pharmaceutical supply chain, they have a 360

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!